Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 11/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8006962 | 0.88 | DPP4 (0.34) | ADRB3ADRA2BADRA2CALDH1A1KDM4E | |
| SCHEMBL13829859 | 0.88 | ADRB3 (0.33) | ADRB3ADRA2BADRA2CHDAC4HDAC1 | |
| SCHEMBL11975940 | 0.87 | HDAC4 (0.33) | ADRB3ADRA2BADRA2CHDAC4HDAC1 | |
| SCHEMBL12777041 | 0.85 | ADRB3 (0.39) | ADRB3ADRA2BADRA2C | |
| SCHEMBL12730850 | 0.85 | ADRB3 (0.39) | ADRB3ADRA2BADRA2C | |
| SCHEMBL13082504 | 0.85 | CTSB (0.42) | HDAC4HDAC1 | |
| SCHEMBL11976284 | 0.85 | CTSB (0.42) | HDAC4HDAC1 | |
| SCHEMBL13082484 | 0.85 | ADRB3 (0.37) | ADRB3ADRA2BADRA2CHDAC4HDAC1 | |
| SCHEMBL8247428 | 0.85 | PSMB9 (0.34) | ADRB3ADRA2BADRA2CALOX15HSD17B10 | |
| SCHEMBL13564324 | 0.84 | HDAC4 (0.38) | ADRB3ADRA2BADRA2CHDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | ADRB3 4572/4885ADRA2B 4492/4885ADRA2C 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.